NovaBridge Biosciences Files 6-K for Q3 2025

TL;DR

NovaBridge (fka I-Mab) filed Q3 2025 6-K. Stock and options info updated.

AI Summary

NovaBridge Biosciences filed a 6-K report as of September 30, 2025. The report details financial information and corporate events. Notably, the company was formerly known as I-Mab, with a name change on May 28, 2019. The filing includes information related to common stock, preferred stock, and employee stock options.

Why It Matters

This filing provides an update on NovaBridge Biosciences' financial status and corporate structure as of Q3 2025, which is crucial for investors tracking the company's performance and any changes.

Risk Assessment

Risk Level: low — This is a routine 6-K filing providing standard financial and corporate information, not indicating any immediate significant risks.

Key Numbers

• Q3 2025 — Reporting Period (The filing covers financial and corporate information up to the third quarter of 2025.)

Key Players & Entities

• NovaBridge Biosciences (company) — Filer
• I-Mab (company) — Former company name
• 2025-09-30 (date) — Period of report
• 2025-12-18 (date) — Filing date
• 2019-05-28 (date) — Date of former company name change

FAQ

Key Financial Figures

• $80 m — deration of the RMB equivalent of up to $80 million, contingent on the achievement of
• $0.0001 — he Company's ordinary shares, par value $0.0001 per share, on the Main Board of the Hon
• $37 m — gregate purchase price of approximately $37 million, and AffaMed subscribed for and p
• $5 million — ont payment to AffaMed in the amount of $5 million. On October 15, 2025, Visara entered
• $7 million — ont payment to AskGene in the amount of $7 million as consideration. In addition, Visara a
• $1.8 million — alth shareholders an upfront payment of $1.8 million and non-contingent payments of $1.2 mil
• $1.2 million — million and non-contingent payments of $1.2 million through 2027. In addition, Bridge Healt
• $3.875 m — eive future milestone payments of up to $3.875 million, subject to the achievement of ce
• $1.95 — of the Company at an offering price of $1.95 per ADS. Net proceeds from the Offering
• $61.2 million — enses payable by us, were approximately $61.2 million. Key Factors Affecting Our Results of
• $7.2 million — ed research and development expenses of $7.2 million and $15.7 million for the nine months e
• $15.7 million — evelopment expenses of $7.2 million and $15.7 million for the nine months ended September 30,
• $14.1 million — our administrative expenses amounted to $14.1 million and $22.3 million, respectively. Inte
• $22.3 m — expenses amounted to $14.1 million and $22.3 million, respectively. Interest Income

Filing Documents

• nbp-20250930.htm (6-K) — 1904KB
• 0001193125-25-323791.txt ( ) — 10231KB
• nbp-20250930.xsd (EX-101.SCH) — 2111KB
• nbp-20250930_htm.xml (XML) — 1638KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NovaBridge Biosciences By : /s/ Xi-Yong Fu Name : Xi-Yong (Sean) Fu Title : Chief Executive Officer Date: December 18, 2025 TABLE OF CONTENTS Page

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS 5

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 6 Overview 6 Recent Business Developments 6 Key Factors Affecting Our Results of Operations 7 Key Components of Results of Operations 9 Results of Operations 11 Critical Accounting Policies and Significant Judgments and Estimates 12 Liquidity and Capital Resources 12 Holding Company Structure 12 INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 F- 2 Condensed Consolidated Statements of Comprehensive Loss for the Nine Months Ended September 30, 2025 and 2024 F- 3 Condensed Consolidated Statements of Changes in Shareholders' Equity for the Nine Months Ended September 30, 2025 and 2024 F- 4 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 F- 5 Notes to the Condensed Consolidated Financial Statements F- 6

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Form 6-K contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended ("the Exchange Act"). All statements other than statements of present and historical facts and conditions are forward-looking statements. Forward-looking statements can often be identified by words or phrases, such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" or the negative of such words or other similar expressions. Such forward-looking statements reflect our current expectations and views of future events, but are not assurances of future performance. Instead, they reflect our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our financial needs, our operational results and other future conditions based on information currently available to us. Such forward-looking statements included in this Form 6-K include, but are not limited to, statements relating to: our proposed dual listing of our ordinary shares on the Stock Exchange of Hong Kong Limited and related public offering; the implementation of our new business model and expected transition into a biotechnology platform company; the timing of initiation and completion, and the progress of our drug discovery and research programs; the timing and likelihood of regulatory filings and approvals; our ability to advance our drug candidates into drugs, and the successful completion of clinical trials; the approval, pricing and reimbursement of our drug candidates; the commercialization of our drug candidates; the market opportunities and competitive landscape of our drug candidates; the payment, receipt and timing of any milestone payments in relation to the licensing agreements; estimates of our costs,

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Our investors should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and related notes for the nine months ended September 30, 2025, as well as our audited consolidated financial statements and related notes included in our Annual Report. In this MD&A, unless otherwise indicated or the context otherwise requires, "we," "us," "our," the "Company," the "Group" and "NovaBridge" refer to NovaBridge Biosciences (formerly known as I-Mab), a Cayman Islands exempted company, and its consolidated subsidiaries, unless the context otherwise required. This MD&A includes trademarks, trade names and service marks, certain of which belong to us and others that are the property of other organizations. Solely for convenience, trademarks, trade names and service marks referred to in this MD&A appear without the , and SM symbols, but the absence of those symbols is not intended to indicate, in any way, that we will not assert our rights or that the applicable owner will not assert its rights to these trademarks, trade names and service marks to the fullest extent under applicable law. We do not intend our use or display of other parties' trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. Our condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. For the periods presented in our condensed consolidated financial statements included elsewhere in this MD&A, our reporting currency is U.S dollars. All references in this MD&A to "$" are to U.S. dollars, and all references to "RMB" are to Renminbi. Tabular amounts are in U.S. dollars in thousand

View Full Filing

View this 6-K filing on SEC EDGAR